[1] 梁紫茵, 周伟泽, 黄秀明, 等. 分析基于4项因素的肝纤维化指数值动态变化对恩替卡韦治疗慢性乙型肝炎肝硬化病人患肝癌风险的预测价值[J]. 安徽医药,2023,27(6):1211-1216. [2] 蔺萍, 金梅. 慢性乙型肝炎患者肝组织PI3K/Akt/mTOR信号通路与HBV病毒载量及肝纤维化程度关系[J]. 中西医结合肝病杂志,2022,32(12):1124-1126,1129. [3] 施文娟, 张妍, 李彩东. 肝纤维化指标对ALT小于2倍正常值上限慢性乙型肝炎患者肝纤维化程度的诊断价值[J]. 临床内科杂志,2022,39(12):842-843. [4] 孙瑞青, 邓娟, 李丰, 等. 慢性乙型肝炎患者血清β-catenin和lncRNA KCNQ1 OT1表达及其在肝纤维化诊断中的应用价值[J]. 疑难病杂志,2023,22(4):402-407. [5] Zhang ZQ, Shi BS, Lu W, et al. Quantitative HBcrAg and HBcAb versus HBsAg and HBV DNA in predicting liver fibrosis levels of chronic hepatitis B patients[J]. Gastroenterol Hepatol,2020,43(9):526-536. [6] Ahmed FA, Bajaifar MS, Ahmed MA, et al. Quantitative HBsAg levels do not identify hepatic fibrosis in HBeAg-negative chronic hepatitis B patients. Saudi J Gastroenterol,2019,25(5):286-292. [7] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志,2015,31(12):1941-1960. [8] 赵景, 何秀波, 谌瑾寰. 肝脏剪切波弹性成像联合GGT/PLT比值诊断慢性乙型肝炎患者肝纤维化价值研究[J]. 实用肝脏病杂志,2023,26(3):332-335. [9] 温青萍, 钱花, 巴桑, 等. 探讨西藏地区恩替卡韦治疗对非酒精性脂肪肝合并慢性乙型肝炎患者肝纤维化程度的影响[J]. 中华肝脏病杂志,2022,30(3):304-308. [10] Mak LY, Hui RW, Fung J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B[J]. J Hepatol,2020,73(4):800-806. [11] 武永萍, 魏占芳, 石栓柱, 等. 瞬时弹性超声成像在评价乙型肝炎肝纤维化严重程度中的价值[J]. 肝脏,2019,24(8):905-907. [12] 王民, 罗文萍, 张冠华, 等. FibroTouch、FibroScan及ARFI在原发性胆汁性胆管炎相关肝纤维化中的诊断价值[J]. 临床肝胆病杂志,2021,37(4):817-822. [13] 周晓颖, 王琳, 崔祖丽. Fibroscan对乙型肝炎并发酒精性肝病患者肝脏纤维化的诊断效果[J]. 肝脏,2019,24(9):1058-1060. [14] 许斌, 孙龙. 瞬时弹性成像技术联合血清SAA、IL-6对乙型肝炎肝纤维化程度的诊断价值[J]. 海南医学院学报,2023,29(1):45-50. [15] 卢秋燕, 卢燕辉, 徐成润. 瞬时弹性成像检测肝硬度联合脾硬度对慢性乙型肝炎肝纤维化诊断的价值[J]. 肝脏,2023,28(3):325-329. [16] Chang XJ, Sun C, Chen Y, et al. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B[J]. World J Gastroenterol,2019,25(32):4764-4778. [17] Nishida Y, Imamura M, Teraoka Y, et al. Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients[J]. J Viral Hepat,2021,28(9):1304-1311. [18] Tseng TC, Liu CJ, Hsu CY, et al. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load[J]. Gastroenterology,2019,157(6):1518-1529. [19] Bian D, Zhao J, Liao H, et al. Serum HBV RNA is associated with liver fibrosis regression in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues[J]. J Viral Hepat,2023,30(4):303-309. [20] Wong DK, Cheng SCY, Mak LL, et al. Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis[J]. Clin Gastroenterol Hepatol,2020,18(2):449-456. |